ACADIA Pharmaceuticals (NASDAQ: ACAD) — Company Overview, News & Financial Data
ACADIA Pharmaceuticals is a biopharmaceutical company developing treatments for CNS disorders like Parkinson's and schizophrenia.
ACADIA Pharmaceuticals
ACADIA Pharmaceuticals (NASDAQ:ACAD) is a biopharmaceutical company focused on the development and commercialization of medicines targeting central nervous system (CNS) disorders. Their portfolio includes innovative treatments for conditions such as Parkinson's disease psychosis, schizophrenia, and major depressive disorder, with their flagship product being a pioneering drug for the management of hallucinations and delusions associated with Parkinson's. ACADIA is actively advancing a diverse range of projects aimed at addressing unmet medical needs in the CNS domain. With a clear objective to enhance patient lives through novel therapies, ACADIA continues to push the boundaries of neuroscience.
Snapshot
Operations
Products and/or services of ACADIA Pharmaceuticals
- NUPLAZID (pimavanserin), the first and only medication approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.
- Trofinetide, a novel treatment under FDA review for Rett Syndrome, aimed at improving the symptoms of this rare, genetic neurodevelopmental disorder.
- ACP-044, an oral, non-opioid pain reliever in Phase 2 clinical trials for the management of acute and chronic pain, offering a potential alternative to opioid-based medications.
- ACP-319, a selective muscarinic M4 receptor agonist in early-stage development, targeting the treatment of psychiatric and neurological disorders, including schizophrenia.
- Pimavanserin development for additional indications, including Alzheimer’s disease psychosis and schizophrenia, expanding its potential therapeutic use beyond Parkinson’s disease psychosis.
- Collaboration with Neuren Pharmaceuticals for the development and commercialization of trofinetide in North America, leveraging mutual resources to advance treatment options for Rett Syndrome.
ACADIA Pharmaceuticals executive team
- Catherine E. Owen AdamsCEO & Director
- Mark C. SchneyerExecutive VP & CFO
- Jennifer J. RhodesExecutive VP, Chief Legal Officer & Secretary
- Elizabeth H. Z. ThompsonExecutive VP and Head of Research & Development
- Thomas Andrew GarnerExecutive VP & Chief Commercial Officer
- Scott CenciSenior VP, Chief Information & Data Officer
- Albert S. KildaniSenior Vice President of Investor Relations & Corporate Communications
- Carl SegerstromChief People Officer
- James K. KiharaSenior Vice President of Finance
- Allyson McMillan-YoungbloodSenior Vice President of Rare Disease Franchise
Latest news about ACADIA Pharmaceuticals
Neuren Pharmaceuticals extends trofinetide patent to 2041
AustraliaAcadia advances remlifanserin program after Phase 2 Alzheimer’s trial results
United StatesNeuren Pharmaceuticals secures European approval for DAYBU (trofinetide) drug
AustraliaAcadia gets EU approval for DAYBU Rett syndrome treatment
United StatesNeuren Pharmaceuticals reports US$125M quarterly sales
AustraliaAcadia Pharmaceuticals receives positive CHMP opinion for DAYBU
United States
Key financials
Reported results for ACADIA Pharmaceuticals, in USD.
- Market cap
- 3.6B
- Revenue (TTM)
- 1.1B
- P/E ratio
- 9.3
- EPS (diluted, TTM)
- 2.2
- Dividend yield
- —
- Profit margin
- 33.4%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 1.1B | 104.8M | 391M | |
| 957.8M | 230.8M | 226.5M | |
| 726.4M | -73.4M | -61.3M | |
| 517.2M | -223.6M | -216M |